Note: This is NOT an IPO. This is a public offering – a NASDAQ Uplisting from the OTC Pink Marketplace, where the stock trades under the symbol “PPCB” – and the company has applied to the NASDAQ to use that symbol – PPCB – after its stock is uplisted to the NASDAQ.

(Incorporated in Delaware)

We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Using our scientific and oncology consultants, we have developed a rational composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.

Note: Net loss and revenue figures are for the fiscal year that ended June 30, 2024. 

(Note: Propanc Biopharma is offering 1.0 million shares at a price range of $4.00 to $6.00 to raise $5.0 million in a public offering in conjunction with Propanc Biopharma’s uplisting to the NASDAQ from the OTC Pink Marketplace, according to its S-1/A filing dated May 23, 2025.)

(Background: This deal previously was a unit offering with each unit consisting of one share of common stock and one warrant, according to an SEC filing in late March 2025. Original Filing: Propanc Biopharma Inc. filed its S-1 on Oct. 30, 2024, and unveiled some of the terms for its unit public offering, which it was planning in conjunction with the proposed uplisting of its common stock to the NASDAQ: 1.5 million units – at a price to be determined – to raise about $9 million. EF Hutton was listed as the sole book-runner. Since then, EF Hutton has changed its name to D. Boral Capital – and the Boral firm is the lead left underwriter of this micro-cap IPO, which dropped the unit structure in the spring of 2025 to become a stock-only public offering/NASDAQ uplisting deal.)